X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-11-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $90.52 | -124,042 | 0 | -100% | -$11,228,720 | |||||
2026-11-10 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $85.09 | -16,035 | 63,445 | -20% | -$1,364,437 | ||||||
| D | 2026-11-09 | ABBV | Abbvie Inc. | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | S - Sale+OE | $293.60 | -40,619 | 81,059 | -33% | -$11,925,738 | |||||
| D | 2026-11-11 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | See Remarks | S - Sale+OE | $34.00 | -23,605 | 54,219 | -30% | -$802,570 | |||||
2026-11-10 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale | $320.05 | -3,000 | 113,476 | -3% | -$960,141 | ||||||
| D | 2026-11-10 | ETON | Eton Pharmaceuticals, Inc. | Erdogan-Trinkaus Ipek | Chief Commercial Officer | S - Sale+OE | $67.41 | -3,500 | 4,081 | -46% | -$235,937 | |||||
2026-11-09 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $54.73 | -5,000 | 5,784 | -46% | -$273,635 | ||||||
| D | 2026-11-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $593.99 | -9,500 | 668,728 | -1% | -$5,642,870 | |||||
| D | 2026-11-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $586.33 | -9,500 | 668,728 | -1% | -$5,570,085 | |||||
| D | 2026-11-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $98.54 | -11,280 | 12,697 | -47% | -$1,111,531 | |||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $15.93 | -129 | 16,091 | -1% | -$2,055 | ||||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $15.93 | -88 | 16,728 | -1% | -$1,402 | ||||||
| DM | 2026-11-09 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $42.86 | -45,003 | 55,755 | -45% | -$1,928,944 | |||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $15.93 | -545 | 63,354 | -1% | -$8,682 | ||||||
2026-11-10 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale | $42.24 | -250,000 | 927,529 | -21% | -$10,559,175 | ||||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $15.93 | -416 | 14,383 | -3% | -$6,627 | ||||||
| D | 2026-11-12 | TEVA | Teva Pharmaceutical Industries Ltd | Sabag Mark | See "Remarks" | S - Sale+OE | $44.14 | -44,710 | 80,760 | -36% | -$1,973,544 | |||||
| D | 2026-11-09 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale+OE | $43.04 | -17,289 | 3,537 | -83% | -$744,049 | |||||
2026-11-10 | ALNY | Alnylam Pharmaceuticals, Inc. | Sigal Charles Elliott | Dir | P - Purchase | $152.25 | +1,600 | 5,046 | +46% | +$243,600 | ||||||
2026-11-09 | ALNY | Alnylam Pharmaceuticals, Inc. | Schulman Amy W | Dir | P - Purchase | $156.82 | +1,910 | 25,959 | +8% | +$299,526 | ||||||
| DM | 2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale+OE | $30.19 | -40,000 | 400,156 | -9% | -$1,207,742 | |||||
2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $29.84 | -100,000 | 3,513,056 | -3% | -$2,983,838 | ||||||
2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $29.84 | -100,000 | 3,513,123 | -3% | -$2,983,678 | ||||||
2026-11-12 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $11.54 | +60,565 | 56,194,662 | 0% | +$698,920 | ||||||
2026-11-10 | AQST | Aquestive Therapeutics, Inc. | Daly Richard J | Dir | P - Purchase | $3.54 | +28,025 | 28,025 | New | +$99,331 | ||||||
| M | 2026-11-09 | AVLN | Avalyn Pharma Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $29.33 | -228,454 | 2,056,081 | -10% | -$6,701,004 | |||||
| M | 2026-11-10 | PHIO | Phio Pharmaceuticals Corp. | Deming David H | Dir | P - Purchase | $0.84 | +12,000 | 49,800 | +32% | +$10,066 | |||||
2026-11-11 | CATX | Perspective Therapeutics, Inc. | Spoor Johan M. | CEO | P - Purchase | $0.81 | +47,000 | 134,683 | +54% | +$37,943 | ||||||
2026-11-11 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $4.06 | +5,000 | 36,007 | +16% | +$20,275 | ||||||
2026-11-10 | MBX | Mbx Biosciences, Inc. | Hoerter Steven L. | COB, Pres, CEO | S - Sale | $54.82 | -4,893 | 98,045 | -5% | -$268,234 | ||||||
| M | 2026-11-09 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CMO, 10% | P - Purchase | $3.99 | +5,016 | 4,690,602 | 0% | +$20,001 | |||||
| M | 2026-11-10 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $4.21 | +70,000 | 12,373,280 | +1% | +$294,500 | |||||
2026-11-09 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale | $1.04 | -40,851 | 946,000 | -4% | -$42,485 | ||||||
| D | 2026-11-10 | ETON | Eton Pharmaceuticals, Inc. | Casamento Charles J | Dir | S - Sale+OE | $66.35 | -80,555 | 0 | -100% | -$5,345,072 | |||||
| D | 2026-11-10 | EWTX | Edgewise Therapeutics, Inc. | Nofi Michael | CFO | S - Sale+OE | $45.43 | -4,442 | 6,495 | -41% | -$201,787 | |||||
| M | 2026-11-06 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +1,949 | 3,035,567 | 0% | +$4,678 | |||||
| D | 2026-11-06 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale+OE | $405.57 | -1,559 | 97,929 | -2% | -$632,277 | |||||
| D | 2026-11-06 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale+OE | $235.95 | -68,808 | 357,567 | -16% | -$16,235,517 | |||||
2026-11-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $584.59 | -1,614 | 668,728 | 0% | -$943,521 | ||||||
| D | 2026-11-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $572.69 | -7,886 | 670,342 | -1% | -$4,516,253 | |||||
| D | 2026-11-09 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $580.00 | -1,210 | 3,240 | -27% | -$701,800 | |||||
2026-11-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | S - Sale | $531.53 | -11,866 | 86,471 | -12% | -$6,307,135 | ||||||
| D | 2026-11-09 | SDGR | Schrodinger, Inc. | Tran Yvonne | EVP, CLO, CPO | S - Sale+OE | $32.85 | -32,000 | 52,683 | -38% | -$1,051,123 | |||||
2026-11-06 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $21.25 | -9,080 | 30,667 | -23% | -$192,950 | ||||||
2026-11-09 | BOLT | Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 10% | P - Purchase | $6.38 | +50,000 | 462,416 | +12% | +$319,000 | ||||||
2026-11-09 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.53 | +140,000 | 1,693,000 | +9% | +$1,194,158 | ||||||
2026-11-09 | PHIO | Phio Pharmaceuticals Corp. | Plott Ronald Todd | Dir | P - Purchase | $0.83 | +18,300 | 60,300 | +44% | +$15,189 | ||||||
2026-11-09 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $0.82 | +25,000 | 789,871 | +3% | +$20,500 | ||||||
2026-11-05 | MTRI | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $13.10 | +2,640 | 98,297 | +3% | +$34,572 | ||||||
2026-11-09 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.86 | +10,000 | 7,783,140 | 0% | +$38,600 | ||||||
2026-11-09 | ARVN | Arvinas, Inc. | Loomis David K | VP, Chief Accounting Officer | S - Sale | $6.36 | -232 | 39,961 | -1% | -$1,475 | ||||||
| D | 2026-11-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.51 | -9,500 | 668,728 | -1% | -$5,362,824 | |||||
2026-11-05 | NATR | Natures Sunshine Products Inc | Prescott Group Capital Management, L.L.C. | 10% | P - Purchase | $9.77 | +291,666 | 2,236,152 | +15% | +$2,849,811 | ||||||
2026-11-05 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $400.82 | -1,115 | 296,829 | 0% | -$446,910 | ||||||
2026-11-05 | OCUL | Ocular Therapeutix, Inc | Saroj Namrata | Chief Business Officer | S - Sale | $6.55 | -35,370 | 220,522 | -14% | -$231,674 | ||||||
| M | 2026-11-05 | NXTC | Nextcure, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $5.10 | +4,686 | 737,956 | +1% | +$23,899 | |||||
2026-11-05 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $2.39 | -53,389 | 545,100 | -9% | -$127,813 | ||||||
2026-11-06 | LXRX | Lexicon Pharmaceuticals, Inc. | Exton Michael | CEO | P - Purchase | $1.66 | +30,064 | 328,496 | +10% | +$49,999 | ||||||
| M | 2026-11-05 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.29 | +70,000 | 7,773,140 | +1% | +$230,510 | |||||
2026-11-05 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $4.22 | -2,826 | 207,546 | -1% | -$11,926 | ||||||
2026-11-04 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale | $319.99 | -282 | 116,476 | 0% | -$90,237 | ||||||
| M | 2026-11-04 | MDGL | Madrigal Pharmaceuticals, Inc. | Baker Bros. Advisors LP | Dir | P - Purchase | $381.49 | +91,806 | 2,244,403 | +4% | +$35,023,032 | |||||
| D | 2026-11-04 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale+OE | $231.36 | -1,413 | 6,512 | -18% | -$326,910 | |||||
2026-11-05 | ABT | Abbott Laboratories | Moreland Mary K | EVP | S - Sale | $116.00 | -3,500 | 118,136 | -3% | -$406,000 | ||||||
2026-11-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $597.76 | -1,960 | 668,728 | 0% | -$1,171,609 | ||||||
| D | 2026-11-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $573.89 | -7,540 | 670,688 | -1% | -$4,327,122 | |||||
| D | 2026-11-04 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $94.71 | -151,300 | 976,643 | -13% | -$14,330,278 | |||||
2026-11-06 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $400.00 | -1,077 | 10,397 | -9% | -$430,800 | ||||||
2026-11-05 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $12.49 | -25,000 | 1,584,208 | -2% | -$312,215 | ||||||
| D | 2026-11-06 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $1.00 | +5,000,000 | 8,588,240 | +139% | +$5,000,000 | |||||
2026-11-05 | BMY | Bristol Myers Squibb Co | Haller Julia A | Dir | S - Sale | $63.31 | -3,800 | 30,279 | -11% | -$240,578 | ||||||
| DM | 2026-11-04 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale+OE | $28.45 | -28,631 | 167,076 | -15% | -$814,669 | |||||
| D | 2026-11-05 | TEVA | Teva Pharmaceutical Industries Ltd | Sabag Mark | See "Remarks" | S - Sale+OE | $41.93 | -46,000 | 80,760 | -36% | -$1,928,729 | |||||
| D | 2026-11-04 | TEVA | Teva Pharmaceutical Industries Ltd | Bergwerk Dov | Interim Cheif Legal Officer | S - Sale+OE | $41.72 | -26,260 | 11,943 | -69% | -$1,095,567 | |||||
| D | 2026-11-04 | REGN | Regeneron Pharmaceuticals, Inc. | Pitofsky Jason | SVP Controller | S - Sale+OE | $942.19 | -4,062 | 4,320 | -48% | -$3,827,159 | |||||
2026-11-04 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +9,000 | 9,452,536 | 0% | +$450 | ||||||
2026-11-04 | PMN | Promis Neurosciences Inc. | Williams Eugene | Dir | P - Purchase | $3.43 | +26,500 | 40,213 | +193% | +$90,895 | ||||||
| M | 2026-11-03 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $1.79 | +18,442 | 3,054,853 | +1% | +$33,019 | |||||
2026-11-03 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $9.60 | -1,299 | 651,413 | 0% | -$12,470 | ||||||
2026-11-03 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $225.37 | -1,000 | 140,394 | -1% | -$225,370 | ||||||
| M | 2026-11-03 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +11,162 | 3,033,618 | 0% | +$26,789 | |||||
2026-11-03 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale | $36.31 | -200,000 | 999,154 | -17% | -$7,262,000 | ||||||
2026-11-05 | LAB | Standard Biotools Inc. | Carey Thomas D. | Dir | P - Purchase | $0.63 | +75,000 | 419,456 | +22% | +$46,898 | ||||||
2026-11-04 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Partners Ix, LLC | 10% | P - Purchase | $10.77 | +2,321,262 | 5,568,424 | +71% | +$24,999,992 | ||||||
2026-11-04 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Fund Xiii, L.P. | 10% | P - Purchase | $10.77 | +2,321,262 | 5,568,424 | +71% | +$24,999,992 | ||||||
2026-11-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $611.06 | -1,723 | 668,728 | 0% | -$1,052,854 | ||||||
| D | 2026-11-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $599.64 | -7,777 | 670,451 | -1% | -$4,663,396 | |||||
2026-11-03 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.04 | -668 | 317,812 | 0% | -$1,363 | ||||||
2026-11-03 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.05 | -3,089 | 1,423,338 | 0% | -$6,317 | ||||||
2026-11-03 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.01 | -668 | 258,020 | 0% | -$1,344 | ||||||
| D | 2026-11-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $598.67 | -8,300 | 45,172 | -16% | -$4,968,933 | |||||
| M | 2026-11-03 | VNDA | Vanda Pharmaceuticals Inc. | Duncan Charles Cliff | Dir | P - Purchase | $3.81 | +10,000 | 108,701 | +10% | +$38,094 | |||||
2026-11-04 | MBX | Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | S - Sale | $53.96 | -373 | 14,026 | -3% | -$20,127 | ||||||
2026-11-05 | OPK | Opko Health, Inc. | Paganelli John A | Dir | S - Sale | $1.81 | -13,601 | 389,914 | -3% | -$24,577 | ||||||
| D | 2026-11-03 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $970.46 | -7,439 | 1,703 | -81% | -$7,219,274 | |||||
2026-11-03 | IRD | Opus Genetics, Inc. | Magrath George | CEO | S - Sale | $3.90 | -28,258 | 2,010,636 | -1% | -$110,184 | ||||||
2026-11-04 | TAK | Takeda Pharmaceutical Co Ltd | Platford Giles Richard | Pres, IBU | S - Sale | $20.90 | -55,617 | 270,253 | -17% | -$1,162,395 | ||||||
| D | 2026-11-04 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $90.00 | -20,000 | 394,137 | -5% | -$1,800,000 | |||||
| D | 2026-11-02 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale+OE | $68.35 | -3,142 | 5,373 | -37% | -$214,746 | |||||
| DM | 2026-11-02 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $70.92 | -4,090 | 11,486 | -26% | -$290,062 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |